strong start gm headwind due cyno
pre-announce link holx revenu yoy
cc growth exclud blood screen ssi cyno upsid driven
better result surgic diagnost breast health off-set disrupt
divest cyno busi close gm declin yoy
our/street est due chiefli cyno book next qtr
ep grew yoy in-lin our/street estim
organ guid rais solid margin room upsid
management updat guid yoy organ revenu
growth account strong cyno divestur smaller
fx headwind vs prior guid top visibl alpha
consensus/our est ep guidanc rais midpoint
includ benefit cyno divestur share buyback
consensu management indic improv gm in-lin
street opm room upsid given cyno heavi opex load
see revenue bracket estimate street est mix
due recent cyno divestur ep in-lin street
updat estim thought share
given higher guid improv visibl post cyno adjust
sale ep estimate unchang
high end guidanc see room upsid given strength across busi
runway ou trend faster-grow tuck-in acquisit modest buy-back
assumpt plan continu deploy capit tuck-in investor
may hope larger ep guidanc boost given strong ytd perform
share see execut stori expect management move
cautious seek rebuild confid consist cyno reiter
buy rate po think holx valuat remain attract given
on-going organ growth improv ep growth potenti
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
core mammographi diagnost
busi deliv solid perform
believ steadier
foot organ growth upsid due
expand offer breast health strength
molecular diagnost mdx busi
believ cynosur cyno headwind less
controversi stock may allow
stock rerat investor focu
po base approxim calendar ep estim
ahead three-year histor averag compani diagnost
med-tech peer multipl believ higher histor multipl
justifi given organ growth upsid breast molecular diagnost
upsid risk po faster growth core diagnost mammographi
gynecolog surgeri end market synergi addit tuck-in deal
downsid risk po competit pressur slower uptak reimburs
new product unfavor chang clinic practic guidelin manag
departur regulatori risk faster declin legaci busi
ivi herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
